Exercise intolerance during post-MI heart failure in rats: Prevention with supplemental dietary propionyl-L-carnitine

Cardiovascular Drugs and Therapy

Volumn 17, Issue 1, 2003, Pages 7-14

  Koh, Stanley G ^a   Brenner, Daniel A ^a   Korzick, Donna H ^b   Tickerhoof, Marlena M ^b   Apstein, Carl S ^a   Saupe, Kurt W ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d 1630 MSC ^*  (United States)

Author keywords

Carnitine; Exercise; Langendorff preparation; Myocardial infarction; Rat

Indexed keywords

CITRATE SYNTHASE; ISOPRENALINE; MUSCLE ENZYME; PROPIONYLCARNITINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; EXERCISE INTOLERANCE; EXERCISE TOLERANCE; HEART CONTRACTION; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE DILATATION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; ISOLATED HEART; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; RAT; TISSUE LEVEL;

ANIMALS; CARNITINE; DIET; DISEASE MODELS, ANIMAL; EXERCISE TOLERANCE; HEART FAILURE, CONGESTIVE; MYOCARDIAL INFARCTION; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION; VENTRICULAR FUNCTION, LEFT;

EID: 0042371703     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024247507014     Document Type: Article

References (39)

1. Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chonic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12:291-299.
2. Brevetti G, di Lisa F, Perna S, et al. Carnitine-related alterations in patients with intermittent claudication: Indication for a focused carnitine therapy. Circulation 1996;93:1685-1689.
3. Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: A double-blind clinical trial. Drugs Exp Clin Res 1999;25:29-36.
4. Greco AV, Mingrone G, Bianchi M, Ghirlanda G. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: Controlled double blind trial versus placebo. Drugs Exp Clin Res 1992;18:69-80.
5. Taylor DJ, Amato A, Hands LJ, et al. Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: A phase II open study. Vasc Med 1996;1:241-245.
6. Micheletti R, Di Paola ED, Schiavone A, et al. Propionyl-L-carnitine limits chronic ventricular dilation after myocardial infarction in rats. Am J Physiol 1993;264:H1111-H1117.
7. Rodrigues B, Xiang H, McNeill JH. Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 1988;37:1358-1364.
8. Schonekess BO, Allard MF, Lopaschuk GD. Propionyl L-carnitine improvement of hypertrophied rat heart function is associated with an increase in cardiac efficiency. Eur J Pharmacol 1995;286:155-166.
9. Sethi R, Dhalla KS, Ganguly PK, Ferrari R, Dhalla NS. Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction. Cardiovasc Res 1999;42:607-615.
10. Broderick TL, Quinney HA, Barker CC, Lopaschuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993;87(3):972-981.
11. Corsico N, Nardone A, Lucreziotti MR, et al. Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: A functional, histologic, and NMR spectroscopic study. Cardiovasc Drugs Ther 1993;7(2):241-251.
12. Di Marzo L, Miccheli A, Sapienza P, et al. 31Phosphorus magnetic resonance spectroscopy to evaluate medical therapy efficacy in peripheral arterial disease. A pilot study. Panminerva Med 1999;41(4):283-290.
13. Paulson DJ, Shug AL. Experimental evidence of the anti-ischemic effect of L-carnitine. In: De Jong JW, Ferrari R, eds. The Carnitine System: A New Therapeutic Approach to Cardiovascular Diseases. Dordrecht: Kluwer, 1995.
14. Pfeffer JM, Pfeffer MA, Frohlich ED. Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 1971;78:957-962.
15. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
16. Jain M, Liao R, Ngoy S, Whittaker P, Apstein CS, Eberli FR. Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodeling in rats. Cardiovascular Res 2000;46(1):66-72.
17. Podesser BK, Siwika DA, Eberli FR, et al. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol 2001;280(3):H984-H991.
18. Eberli FR, Weinberg EO, Grice WN, Horowitz GL, Apstein CS. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res 1991;68:466-481.
19. Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res 1981;49:618-626.
20. Longo A, Bruno G, Curti S, Mancinelli A, Miotto G. Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. J Chromatogr B Biomed Appl 1996;686:129-139.
21. Srere P. Citrate synthase. Methods in Enzymology. 1969; 3-5.
22. Pfeffer MA, Lamas GA, Vaughan DE, Paris AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1998;319(2):80-86.
23. Pfeffer MA, Pfeffer JM, Lamas GA. Development and prevention of congestive hart failure following myocardial infarction. Circulation 1993;87(5 suppl):IV120-IV125.
24. Roger VL, Jacobsen SJ, Pellikka PA, Miller TD, Bailey KR, Gersh BJ. Prognostic value of treadmill exercise testing: A population-based study in Olmsted County, Minnesota. Circulation 1998;98:2836-2841.
25. Snader CE, Marwick TH, Pashkow FJ, Harvey SA, Thomas JD, Lauer MS. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: Report of 3,400 patients from a single center. J Am Coll Cardiol 1997;30:641-648.
26. Vanhees L, Fagard R, Thijs L, Staessen J, Amery A. Prognostic significance of peak exercise capacity in patients with coronary artery disease. J Am Coll Cardiol 1994;23:358-363.
27. Adamopoulos S, Coats AJ, Brunotte F, et al. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 1993;21:1101-1106.
28. Colucci WS, Ribeiro JP, Rocco MB, et al. Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization. Circulation 1989;80:314-323.
29. De Sousa E, Veksler V, Bigard X, Mateo P, Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Circulation 2000;102:1847-1853.
30. Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: The L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995;26:380-387.
31. Pfeifer PC, Musch TI, McAllister RM. Skeletal muscle oxidative capacity and exercise tolerance in rats with heart failure. Med Sci Sports Exerc 2001;33:542-548.
32. Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: Results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J 2000;139:S124-S130.
33. Monassier L, Riehl V, Lienhard JP, Tibirica E, Feldman J, Bousquet P. Effects of ifenprodil and baclofen on exercise-induced increase of myocardial oxygen demand in normotensive rats. J Pharmacol Exp Ther 1999;290(3):1188-1194.
34. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res 2001;51:21-29.
35. Nakamura M. Peripheral vascular remodeling in chronic heart failure: Clinical relevance and new conceptualization of its mechanisms. J Card Fail 1999;5:127-138.
36. Musch TI, Terrell JA. Skeletal muscle blood flow abnormalities in rats with a chronic myocardial infarction: Rest and exercise. Am J Physiol 1992;262:H411-H419.
37. Clark A, Coats A. Mechanisms of exercise intolerance in cardiac failure: Abnormalities of skeletal muscle and pulmonary function. Curr Opin Cardiol 1994;9:305-314.
38. Brass EP. Supplemental carnitine and exercise. Am J Clin Nutr 2000;72:618S-623S.
39. Gleim GG, Glace B. Carnitine as an ergogenic aid in health and disease. J Am Coll Nutr 1998;17:203-204.